Cell Cycle Genes in a Mouse Mammary Hyperplasia Model

Overview

Journal J Mammary Gland Biol Neoplasia

Date 2004 Apr 15

PMID 15082920

Citations 1

Authors

Thenaa K Said

Daniel Medina

Affiliations

Soon will be listed here.

Abstract

Human mammary epithelial cells emerge spontaneously from senescence, exhibiting eroding telomeric sequences, and ultimately enter crisis to generate the type of chromosomal abnormalities seen in early stages of breast cancer. In a mouse mammary tumor model, the spontaneous escape of senescence can be observed as an increase in DNA synthesis that is reflected by alterations in the cell cycle profile and increases in the expression levels and activities of cell cycle molecular components. This review provides an overview of gene alterations in the cell cycle components in mouse mammary hyperplasia.

Citing Articles

Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression.

Schaefer J, Sabherwal Y, Shi H, Sriraman V, Richards J, Minella A J Biol Chem. 2010; 285(15):11258-69.

PMID: 20139077 PMC: 2857004. DOI: 10.1074/jbc.M109.073932.

References

Koff A, Giordano A, Desai D, Yamashita K, Harper J, Elledge S . Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science. 1992; 257(5077):1689-94. DOI: 10.1126/science.1388288. View

Elledge S . Cell cycle checkpoints: preventing an identity crisis. Science. 1996; 274(5293):1664-72. DOI: 10.1126/science.274.5293.1664. View

St Croix B, Sheehan C, Rak J, Florenes V, Slingerland J, Kerbel R . E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol. 1998; 142(2):557-71. PMC: 2133056. DOI: 10.1083/jcb.142.2.557. View

Medina D, Kittrell F . Immortalization phenotype dissociated from the preneoplastic phenotype in mouse mammary epithelial outgrowths in vivo. Carcinogenesis. 1993; 14(1):25-8. DOI: 10.1093/carcin/14.1.25. View

Keyomarsi K, OLeary N, Molnar G, Lees E, Fingert H, Pardee A . Cyclin E, a potential prognostic marker for breast cancer. Cancer Res. 1994; 54(2):380-5. View

Elledge S, Harper J . Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol. 1994; 6(6):847-52. DOI: 10.1016/0955-0674(94)90055-8. View

Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H . Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol. 2002; 160(2):605-12. PMC: 1850646. DOI: 10.1016/S0002-9440(10)64880-8. View

Jerry D, Kuperwasser C, Downing S, Pinkas J, He C, Dickinson E . Delayed involution of the mammary epithelium in BALB/c-p53null mice. Oncogene. 1998; 17(18):2305-12. DOI: 10.1038/sj.onc.1202157. View

Sicinski P, Weinberg R . A specific role for cyclin D1 in mammary gland development. J Mammary Gland Biol Neoplasia. 2000; 2(4):335-42. DOI: 10.1023/a:1026391128117. View

10.

Said T, Medina D . Cell cyclins and cyclin-dependent kinase activities in mouse mammary tumor development. Carcinogenesis. 1995; 16(4):823-30. DOI: 10.1093/carcin/16.4.823. View

11.

Koff A, Ohtsuki M, Polyak K, Roberts J, Massague J . Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science. 1993; 260(5107):536-9. DOI: 10.1126/science.8475385. View

12.

Nevins J, Leone G, DeGregori J, Jakoi L . Role of the Rb/E2F pathway in cell growth control. J Cell Physiol. 1997; 173(2):233-6. DOI: 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F. View

13.

Clarke C, Sutherland R . Progestin regulation of cellular proliferation. Endocr Rev. 1990; 11(2):266-301. DOI: 10.1210/edrv-11-2-266. View

14.

Kuhling H, Alm P, Olsson H, Ferno M, Baldetorp B, Parwaresch R . Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol. 2003; 199(4):424-31. DOI: 10.1002/path.1322. View

15.

Loden M, Nielsen N, Roos G, Emdin S, Landberg G . Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene. 1999; 18(16):2557-66. DOI: 10.1038/sj.onc.1202488. View

16.

Lenz H . Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev. 2003; 29 Suppl 1:41-8. DOI: 10.1016/s0305-7372(03)00082-3. View

17.

Marsh K, Varley J . Frequent alterations of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry. Br J Cancer. 1998; 77(9):1460-8. PMC: 2150197. DOI: 10.1038/bjc.1998.240. View

18.

Rey M, Fernandez P, Jares P, Munoz M, Nadal A, Peiro N . p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol. 1998; 184(3):265-71. DOI: 10.1002/(SICI)1096-9896(199803)184:3<265::AID-PATH8>3.0.CO;2-8. View

19.

Tsihlias J, Kapusta L, Slingerland J . The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med. 1999; 50:401-23. DOI: 10.1146/annurev.med.50.1.401. View

20.

Xu L, Sgroi D, Sterner C, Beauchamp R, Pinney D, Keel S . Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res. 1994; 54(20):5262-4. View